Luke Buizen

594 total citations
27 papers, 306 citations indexed

About

Luke Buizen is a scholar working on Public Health, Environmental and Occupational Health, Oncology and Reproductive Medicine. According to data from OpenAlex, Luke Buizen has authored 27 papers receiving a total of 306 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Public Health, Environmental and Occupational Health, 7 papers in Oncology and 6 papers in Reproductive Medicine. Recurrent topics in Luke Buizen's work include Ovarian cancer diagnosis and treatment (6 papers), Pain Management and Opioid Use (5 papers) and Opioid Use Disorder Treatment (5 papers). Luke Buizen is often cited by papers focused on Ovarian cancer diagnosis and treatment (6 papers), Pain Management and Opioid Use (5 papers) and Opioid Use Disorder Treatment (5 papers). Luke Buizen collaborates with scholars based in Australia, Canada and United Kingdom. Luke Buizen's co-authors include Val Gebski, David Sullivan, Alicia J. Jenkins, Anthony Keech, Anne Lanceley, Paul Donnellan, Michael Friedländer, Eriko Aotani, Amit M. Oza and Jonathan S. Berek and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Diabetologia.

In The Last Decade

Luke Buizen

25 papers receiving 301 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Luke Buizen Australia	11	112	73	58	50	40	27	306
Zahra Najmi Iran	12	44 0.4×	45 0.6×	135 2.3×	97 1.9×	49 1.2×	45	453
Claudia Friedl Austria	10	45 0.4×	48 0.7×	26 0.4×	28 0.6×	145 3.6×	19	544
Hidenori Oguchi Japan	13	61 0.5×	82 1.1×	54 0.9×	66 1.3×	26 0.7×	38	408
Pamela Ng Canada	9	128 1.1×	44 0.6×	11 0.2×	16 0.3×	20 0.5×	20	301
Patrícia Nessralla Alpoim Brazil	16	69 0.6×	24 0.3×	19 0.3×	69 1.4×	39 1.0×	37	664
Shari Ludlam United States	2	62 0.6×	42 0.6×	39 0.7×	70 1.4×	30 0.8×	3	513
D. Morgan United States	8	58 0.5×	67 0.9×	13 0.2×	61 1.2×	34 0.8×	16	376
Phoebe Finneran United States	6	27 0.2×	101 1.4×	50 0.9×	81 1.6×	29 0.7×	8	399
Andrese Aline Gasparin Brazil	12	24 0.2×	34 0.5×	18 0.3×	15 0.3×	17 0.4×	31	324

Countries citing papers authored by Luke Buizen

Since Specialization

Citations

This map shows the geographic impact of Luke Buizen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luke Buizen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luke Buizen more than expected).

Fields of papers citing papers by Luke Buizen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luke Buizen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luke Buizen. The network helps show where Luke Buizen may publish in the future.

Co-authorship network of co-authors of Luke Buizen

This figure shows the co-authorship network connecting the top 25 collaborators of Luke Buizen. A scholar is included among the top collaborators of Luke Buizen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luke Buizen. Luke Buizen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Siriwardana, Amanda, Luke Buizen, Min Jun, et al.. (2025). Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial. Diabetes Obesity and Metabolism. 27(4). 1972–1979. 1 indexed citations

Wick, James, Daniel Bekele Ketema, Luke Buizen, et al.. (2025). Assessing patterns of chronic kidney disease care in Australian primary care: a retrospective cohort study of a national general practice dataset. The Lancet Regional Health - Western Pacific. 57. 101541–101541.

Bharat, Chrianna, Luke Buizen, Jacqueline Close, et al.. (2024). 181 Age-related risk of serious fall events associated with opioid analgesic use. Abstracts. A35.1–A35. 1 indexed citations

Gisev, Natasa, Luke Buizen, Andrea L. Schaffer, et al.. (2023). Five-Year Trajectories of Prescription Opioid Use. JAMA Network Open. 6(8). e2328159–e2328159. 8 indexed citations

Bharat, Chrianna, Natasa Gisev, Sebastiano Barbieri, et al.. (2023). Prescription opioid use among people with opioid dependence and concurrent benzodiazepine and gabapentinoid exposure: An analysis of overdose and all-cause mortality. International Journal of Drug Policy. 123. 104287–104287. 3 indexed citations

Gisev, Natasa, Sallie‐Anne Pearson, Timothy Dobbins, et al.. (2023). Cohort profile: POPPY II – a population-based cohort examining the patterns and outcomes of prescription opioid use in New South Wales, Australia. BMJ Open. 13(5). e068310–e068310. 3 indexed citations

Kennedy, Glen, Siok‐Keen Tey, Luke Buizen, et al.. (2021). A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis. Blood. 137(14). 1970–1979. 32 indexed citations

Moore, David, et al.. (2021). The risk of postoperative deterioration of non-cardiac surgery patients with ICU referral status who are admitted to the regular ward: a retrospective observational cohort study. Patient Safety in Surgery. 15(1). 10–10. 3 indexed citations

Ling, Joanna, Digsu N. Koye, Luke Buizen, et al.. (2021). Temporal trends in co‐morbidities and cardiometabolic risk factors at the time of type 2 diabetes diagnosis in the UK. Diabetes Obesity and Metabolism. 23(5). 1150–1161. 11 indexed citations

10.

Roncolato, Felicia, Rachel O’Connell, Florence Joly, et al.. (2019). Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG symptom benefit study (SBS). Gynecologic Oncology. 156(1). 45–53. 6 indexed citations

11.

Rico, Gonzalo Tapia, Timothy Price, Niall C. Tebbutt, et al.. (2019). Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial. Clinical Colorectal Cancer. 18(2). 141–148. 19 indexed citations

12.

Ansquer, Jean-Claude, David Sullivan, Alicia J. Jenkins, et al.. (2018). Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. The Lancet Diabetes & Endocrinology. 6(4). 310–318. 43 indexed citations

13.

Lord, Sarah J., Harold Hudson, Chee Khoon Lee, et al.. (2018). Performance of four published risk models to predict sentinel lymph-node involvement in Australian women with early breast cancer. The Breast. 41. 82–88. 3 indexed citations

14.

Roncolato, Felicia, Dominique Berton-Rigaud, Rachel O’Connell, et al.. (2017). Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). Gynecologic Oncology. 148(1). 36–41. 30 indexed citations

15.

King, Madeleine, Martin R. Stockler, Rachel O’Connell, et al.. (2017). Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. Quality of Life Research. 27(1). 59–74. 33 indexed citations

16.

Roncolato, Felicia, Florence Joly, Rachel O’Connell, et al.. (2017). Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer—The GCIG Symptom Benefit Study. The Oncologist. 22(9). 1117–1124. 18 indexed citations

17.

Roncolato, Felicia, Florence Joly, Rachel O’Connell, et al.. (2017). Predictors of stopping chemotherapy early and short survival in patients with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) who have had ≥3 lines of prior chemotherapy: The GCIG symptom benefit study (SBS).. Journal of Clinical Oncology. 35(15_suppl). 5575–5575. 1 indexed citations

18.

Roncolato, Felicia, Rachel O’Connell, Luke Buizen, et al.. (2016). Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG symptom benefit study (SBS).. Journal of Clinical Oncology. 34(15_suppl). 5508–5508. 2 indexed citations

19.

Williams, Kathryn, David Sullivan, Geoffrey C. Nicholson, et al.. (2015). Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Metabolism. 65(5). 783–793. 22 indexed citations

20.

Ong, Kwok Leung, Andrzej S. Januszewski, Rachel O’Connell, et al.. (2015). Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia. 58(9). 2035–2044. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact